Viimeisimmät kokeilut


EudraCT Number: 2020-000976-40 Sponsor Protocol Number: ION373-CS1 Start Date:
Sponsor Name: Ionis Pharmaceuticals, Inc
Full Title: A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients with Alexand...
Medical condition: Alexander Disease
Disease: Version SOC Term Classification Code Term Level
22.1 10010331 - Congenital, familial and genetic disorders 10083059 Alexander disease PT
Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
Trial protocol: GB (GB - no longer in EU/EEA) NL (Ongoing) IT (Ongoing)
Trial results: (No results available)

EudraCT Number: 2009-017477-38 Sponsor Protocol Number: MEK112110 Start Date:
Sponsor Name: GlaxoSmithKline Research & Development Ltd
Full Title: An Open-Label, Dose-Escalation, Phase IB/ II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor GSK1120212 in Combination with Oral Evero...
Medical condition: Solid Tumors
Disease: Version SOC Term Classification Code Term Level
12.1 10059515 Non-small cell lung cancer metastatic LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Completed) ES (Prematurely Ended)
Trial results: View results
EudraCT Number: 2009-009320-36 Sponsor Protocol Number: 28431754DIA3009 Start Date:
Sponsor Name: Janssen Cilag International NV
Full Title: A Randomized, Double-Blind, 3-Arm Parallel-Group, 2-Year (104-Week), Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ 28431754 100 mg and JNJ-28431754 300 mg Compared Wit...
Medical condition: Type 2 Diabetes Mellitus
Disease: Version SOC Term Classification Code Term Level
9.1 10045242 Type II diabetes mellitus LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: NO (Completed) DE (Completed) FI (Completed) SK (Completed) DK (Completed) BG (Completed)
Trial results: View results

EudraCT Number: 2009-015125-36 Sponsor Protocol Number: NCT00934687 Start Date:
Sponsor Name: Medical School Hannover. Department of Psychiatry, Social Psychiatry and Psychotherapy
Full Title: Clostridium botulinum Typ A Neurotoxinkomplex zur adjuvanten Behandlung von depressiven Störungen – Eine randomisierte, kontrollierte Pilotstudie
Medical condition: Botulinum Toxin for the Treatment of Depression
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults Gender: Male, Female
Trial protocol: DE (Completed)
Trial results: (No results available)
EudraCT Number: 2006-000846-38 Sponsor Protocol Number: R076477-BIM-3004 Start Date:
Sponsor Name: Janssen-Cilag International N.V.
Full Title: A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Extended-Release Paliperidone as Maintenance Treatment After an ...
Medical condition: Bipolar I disorder, most recent maniac or mixed episode
Disease: Version SOC Term Classification Code Term Level
9.0 10004939 LLT
Population Age: Adults Gender: Male, Female
Trial protocol: DE (Completed)
Trial results: View results

EudraCT Number: 2008-005168-15 Sponsor Protocol Number: CQAV680A2201 Start Date:
Sponsor Name: Novartis Pharma Services AG
Full Title: A randomized, double-blind, two way cross-over, proof of concept study to compare the efficacy, safety, pharmacokinetics and pharmacodynamics of two-week oral administration of QAV680 versus placeb...
Medical condition: Mild to moderate persistent asthma, steroid-free patients
Disease: Version SOC Term Classification Code Term Level
9.1 10003553 Asthma LLT
Population Age: Adults Gender: Male, Female
Trial protocol: DE (Completed)
Trial results: View results
EudraCT Number: 2018-000127-14 Sponsor Protocol Number: NCT-2017-0516 Start Date:
Sponsor Name: Heidelberg University Hospital
Full Title: INFORM2 exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
Medical condition: This trial investigates a novel combination treatment regimen using immune checkpoint inhibition and epigenetic therapy in children with relapsed/refractory/progressive high-risk solid tumors or CN...
Disease: Version SOC Term Classification Code Term Level
Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
Trial protocol: SE (Ongoing) DE (Ongoing) NL (Ongoing) FR (Ongoing) AT (Ongoing)
Trial results: (No results available)

EudraCT Number: 2019-004942-14 Sponsor Protocol Number: IJB-LOB-2019 Start Date:
Sponsor Name: Institut Jules Bordet
Full Title: Neoadjuvant study of targeting ROS1 in combination with endocrine therapy in invAsive Lobular carcINoma of the breast
Medical condition: ER-positive/HER2-negative invasive lobular carcinoma
Disease: Version SOC Term Classification Code Term Level
20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073096 Invasive lobular breast carcinoma PT
Population Age: Adults, Elderly Gender: Female
Trial protocol: BE (Ongoing)
Trial results: (No results available)
EudraCT Number: 2019-004016-58 Sponsor Protocol Number: WPD-201P Start Date:
Sponsor Name: WPD Pharmaceuticals Sp. z o.o.
Full Title: A Phase 1, Multicenter, Open-label, Dose Escalation Study of the Safety and Pharmacokinetics of Intravenously Infused Berubicin® in Pediatric Patients with Progressive, Refractory, or Recurrent Hig...
Medical condition: High Grade Gliomas
Disease: Version SOC Term Classification Code Term Level
Population Age: Children, Adolescents, Under 18 Gender: Male, Female
Trial protocol: PL (Prematurely Ended)
Trial results: (No results available)

EudraCT Number: 2018-001516-30 Sponsor Protocol Number: GDX-44-007 Start Date:
Sponsor Name: GUERBET
Full Title: Pharmacokinetics, safety and efficacy of a new gadolinium-based contrast agent, gadopiclenol, in pediatric patients from 2 to 17 years of ageundergoing contrast-enhanced MRI.
Medical condition: Pediatric subjects from 2 to 17 years old scheduled to undergo routine gadolinium contrast enhanced Magnetic Resonance Imaging of Central Nervous System
Disease: Version SOC Term Classification Code Term Level
21.1 10022891 - Investigations 10029817 Nuclear magnetic resonance imaging brain PT
21.1 10022891 - Investigations 10072232 Nuclear magnetic resonance imaging spinal PT
Population Age: Children, Adolescents, Under 18 Gender: Male, Female
Trial protocol: SK (Ongoing) PL (Completed) BG (Completed)
Trial results: (No results available)
3